Cdc7-Dbf4-mediated phosphorylation of HSP90-S164 stabilizes HSP90-HCLK2-MRN complex to enhance ATR/ATM signaling that overcomes replication stress in cancer

An Ning Cheng1,2, Chi-Chen Fan3,4, Yu-Kang Lo1, Cheng-Liang Kuo1, Hui-Chun Wang5, I.-Hsin Lien2, Shu-Yu Lin6, Chung-Hsing Chen1, Shih Sheng Jiang1, I.-Shou Chang1, Hsueh-Fen Juan7,8, Ping-Chiang Lyu2 & Alan Yueh-Luen Lee1,9

Cdc7-Dbf4 kinase plays a key role in the initiation of DNA replication and contributes to the replication stress in cancer. The activity of human Cdc7-Dbf4 kinase remains active and acts as an effector of checkpoint under replication stress. However, the downstream targets of Cdc7-Dbf4 contributed to checkpoint regulation and replication stress-support function in cancer are not fully identified. In this work, we showed that aberrant Cdc7-Dbf4 induces DNA lesions that activate ATM/ATR-mediated checkpoint and homologous recombination (HR) DNA repair. Using a phosphoproteome approach, we identified HSP90-S164 as a target of Cdc7-Dbf4 in vitro and in vivo. The phosphorylation of HSP90-S164 by Cdc7-Dbf4 is required for the stability of HSP90-HCLK2-MRN complex and the function of ATM/ATR signaling cascade and HR DNA repair. In clinically, the phosphorylation of HSP90-S164 indeed is increased in oral cancer patients. Our results indicate that aberrant Cdc7-Dbf4 enhances replication stress tolerance by rewiring ATR/ATM mediated HR repair through HSP90-S164 phosphorylation and by promoting recovery from replication stress. We provide a new solution to a subtyping of cancer patients with dominant ATR/HSP90 expression by combining inhibitors of ATR-Chk1, HSP90, or Cdc7 in cancer combination therapy.

Cell cycle checkpoints are complex surveillance mechanisms that are used to ensure genomic stability and successful repair of DNA damage before entering next phase. ATM (ataxia telangiectasia mutated) and ATR (ataxia telangiectasia and Rad3-related protein) are two major kinases that are crucial for detecting aberrant DNA structures and activating DNA damage response (DDR)1. Different types of DNA lesions activate different but overlapping DDR pathways. DNA double stranded breaks (DSBs) sensed by the Mre11/Rad50/Nbs1 (MRN) complex activate the ATM-Chk2 signaling2; single-stranded DNAs (ssDNA) induced by replication stress activate the ATR-Chk1 signaling along with the ATRIP, HCLK2, and TopBP13,4. The kinases are stimulated to transduce...
the signal to effector proteins that launch a cascade of events that causes cell cycle arrest, apoptosis and/or DNA repair.

Replication stress is now recognized as a cancer hallmark. Replication stress is represented by stalling of replication forks, their collapse, and DSBs formation. The extent of replication stress is under the tight control of ATR-Chk1 S-phase checkpoint and DNA repair including homologous recombination (HR) repair that ensure genomic stability. The S-phase checkpoint inhibits further firing at late origin to slow down DNA replication and prevents progression into mitosis in DDR. Unfortunately, mutations in the checkpoint or DNA repair are found in many advanced stage cancers. To cope with the increased replication stress, cancer cells bearing checkpoint- or repair-deficiency paradoxically amplify ATR-Chk1 signaling to overcome the stress for proliferation and survival. However, how replication stress induces extensive activation of ATR-Chk1 signaling for DNA damage tolerance in cancer still is needed to explore.

Cdc7-Dbf4 kinase plays pivotal roles in the initiation of DNA replication and DNA repair in many types of cancer including oral cancer. Cdc7-Dbf4 also is involved in other DNA metabolism events including meiotic recombination, translesion synthesis (TLS), and S phase checkpoint. Initially, Cdc7-Dbf4 kinase from yeast was considered as a target of S-phase checkpoint because the activity of Cdc7-Dbf4 was inhibited upon replication stress. However, accumulating evidences suggested that human Cdc7-Dbf4 remains active upon replication stress, indicating that human Cdc7-Dbf4 acts as an upstream effector to monitor S-phase checkpoint signaling. In addition, Cdc7-Dbf4 promotes checkpoint recovery, TLS, and fork protection to increase cell survival under replication stress.

Indeed, overexpression of Cdc7-Dbf4 is associated with tumor advanced clinical stage, patient survival, cell cycle deregulation, and genomic instability. We previously found that increased Cdc7 inhibits DNA damage-induced apoptosis and increases the survival of cancer cells upon DNA damage response. However, the targets of human Cdc7-Dbf4 in the detailed mechanism in the coordination of checkpoint and replication stress-support function are still missing.

HSP90 is a molecular chaperone with more than 200 identified client proteins including numerous oncoproteins, such as AKT. HSP90 plays an important role in S-phase checkpoint and DNA repair for cellular adaptation. HSP90 binds the component proteins of ATR signaling, ATR, MRN complex, and HCLK2-TTI1/2 complex. In addition, the chaperone function of HSP90 is regulated by post-translational modification. Thus, whether the phosphorylation of HSP90 contributes to the regulation of S-phase checkpoint and DNA repair is still unknown. In this paper, we unveiled a novel role of Cdc7-Dbf4 in the regulation of ATR/ATM checkpoint signaling and HR DNA repair in cancer by phosphorylating HSP90 at S164.

Results

Overexpression of Cdc7 induces replication that causes DNA DSB and activates ATM/ATR-mediated checkpoint. Cdc7 and Dbf4 are overexpressed in many types of cancer including oral cancer. To explore how increased Cdc7-Dbf4 contributes to DNA damage tolerance that contributes to tumorigenesis, we tried to solve the puzzle by triggering Cdc7 overexpression in cells. First, Cdc7 and Dbf4 accumulated on stalled fork and caused more MCM2 phosphorylation when cells were treated with replication stress agents, UV, HU or aphidicolin (Fig. 1A). RPA1, a single-stranded DNA (ssDNA)-binding protein, and γH2AX, a marker of double-stranded breaks (DSBs), were also accumulated on the damaged DNA (Fig. 1A). This result suggests that Cdc7-Dbf4 is activated and correlated with ssDNA/DSB formation under replication stress. We used the adenovirus expressing Cdc7 (Ad-myc-Cdc7) to increase Cdc7 activity and Cdc7 kinase dead mutant (Ad-myc-Cdc7 KD) to inhibit Cdc7 activity in cells, which was confirmed by the status of phosphorylation of MCM2 at S53 or S40/S41 (Fig. 1B and Supplementary Figure 1A) and the Cdc7-dependent chromatin loading of initiation factor Cdc45 (Supplementary Figure 1A). As expected, the cells expressing excess Cdc7 showed a strong positive γH2AX signal in a dose-dependent manner (Fig. 1B,C), which was confirmed by the comet assay (Fig. 1D) and immunofluorescence staining (Fig. 1E and Supplementary Figure 2A). Furthermore, increased Cdc7 activity promoted the accumulation of Cdc6, Cdt1, and TopBP1 on chromatin in a dose-dependent manner but inhibited the chromatin binding of Cdc45 and PCNA when Cdc7 was highly expressed (Fig. 1C). This result suggests that overexpressed Cdc7-Dbf4 always augments pre-replicative complex (pre-RC) assembly of replication but represses origin firing of replication because Cdc7 overexpression activates checkpoint. These results indicate that increased Cdc7 activity leads to the formation of DSBs that activates S-phase checkpoint. Indeed, increased Cdc7 promotes the activation of ATR-mediated S-phase checkpoint (Fig. 1F). We confirmed the S-checkpoint activation by the extent of BrdU incorporation when Cdc7 was overexpressed. The BrdU positive cells were reduced when Cdc7 was overexpressed and were reduced more by Ad-Cdc7 KD, and UV treatment was a positive control (Fig. 1G). Consistently, FACS analysis also showed that overexpressed Cdc7 inhibits the signal of BrdU and increases γH2AX-positive cells after double staining with BrdU and γH2AX in the cells overexpressing Cdc7 (Supplementary Figure 2B). These data showed that increased Cdc7 upregulates the initiation of DNA replication, but excess Cdc7 causes DSB formation that activates S-phase checkpoint signaling.

Overexpression of Cdc7 initially activates S-phase checkpoint and delays cell cycle for DNA repair and then promotes recovery from replication stress. S-phase checkpoint is considered as a barrier to tumorigenesis because it prevents DNA damage from transmitting to daughter cells. To study the conflicting observation on tumorigenesis that overexpressed Cdc7 activates S-phase checkpoint and DNA damage tolerance, U2OS overexpressing Cdc7 cells were treated with HU and observed the effect on cell proliferation and cell cycle. The cell viability of U2OS cells overexpressing Cdc7 was significantly higher than control cells treated with HU (Fig. 2A), which is consistent with previous finding that upregulated Cdc7 protects cells from DNA damage agents. To understand the effect of Cdc7 overexpression on checkpoint regulation, the HU-treated cells were released from the replication stress under Cdc7 overexpression or not (Fig. 2B). The results showed that Cdc7-overexpressed cells were arrested in G1/S phase (3 hr) and delayed to enter S (6 hr) and M phase (9
Figure 1. Cdc7 overexpression causes DNA lesions and activates ATM/ATR-mediated checkpoint. (A) Cdc7 and Dbf4 accumulate on stalled fork to activate more MCM2 phosphorylation and cause the formation of DNA lesions upon replication stress. Chromatin fractions were isolated from U2OS cells after mock treatment (No), or UV (50 J/m²), HU (1 mM, 24h after), or Aphidicolin (Aph, 1 µg/ml, 24h after) and were applied to immunoblotting. Equal amounts of input protein were subjected to immunoblotting using anti-Cdc7, anti-Dbf4, anti-MCM2, anti-γ-H2AX, and anti-RPA1 antibodies. Ku70 was served as a loading control. (B) Cdc7 overexpression induces DSB formation. U2OS was infected with Ad-Cdc7 (0.6, 1.2, 2.4, or 3.6 × 10⁸ pfu/ml) or Ad-Vec (3.6 × 10⁸ pfu/ml) for 48h. The lysates were analyzed by Western blotting using the indicated antibodies. The expression of endogenous Cdc7 (Endo-Cdc7) and adenovirally introduced Myc tagged Cdc7 (Myc-Cdc7) is shown as indicated. (C) Cdc7 overexpression triggers the initiation of DNA replication and causes DSB formation that activates S-checkpoint. U2OS was infected with Ad-Cdc7 (0.3, 0.6, 1.2, 2.4, 3.6, or 7.2 × 10⁸ pfu/ml) or Ad-Vec (3.6 × 10⁸ pfu/ml) for 48h. Chromatin fractions were isolated and analyzed by immunoblotting. Equal amounts of input protein were subjected to immunoblotting using anti-Cdc7, anti-Cdc6, anti-Cdt1, anti-TopBP1, anti-Cdc45, anti-PCNA, and anti-γ-H2AX antibodies. Ku70 was served as a loading control. The expression of endogenous Cdc7 (Endo-Cdc7) and adenovirally introduced Myc tagged Cdc7 (Myc-Cdc7) is shown. (D) Comet assays indicate DSB formation when Cdc7 is overexpressed. U2OS was infected with Ad-Cdc7 using different viral titers (0.6 × 10⁸ pfu/ml, MOI = 20; 1.2 × 10⁸ pfu/ml, MOI = 40; 2.4 × 10⁸ pfu/ml, MOI = 80; 3.6 × 10⁸ pfu/ml, MOI = 100; 7.2 × 10⁸ pfu/ml, MOI = 200) or Ad-GFP control. Olive moment for each condition was measured using the Comet Score software (TriTek Corporation, Sumerduck, VA, USA). Fifty cells were counted for each experiment. Two typical cells with or without comet tails are shown on the right. Results are presented as range of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. (E) Cdc7 overexpression triggers γH2AX formation by immunofluorescence analysis. U2OS cells were infected with Ad-Cdc7 (2.4 × 10⁸ pfu/ml) or Ad-Vec for 48h and immunostaining was performed by using antibodies toward γH2AX. U2OS cells treated with hydroxyurea (HU, 1 mM) for 16h only were used as a positive control. DAPI was used for nuclear staining. The graph with error bars is shown in the right panel. Results are presented as range of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. (F) Cdc7 overexpression activates ATR-mediated checkpoint. U2OS was infected with Ad-Cdc7 (0.3, 0.6, 1.2, 2.4, 3.6, or 7.2 × 10⁸ pfu/ml) or Ad-Vec (3.6 × 10⁸ pfu/ml) for 48h. The lysates were analyzed by immunoblotting using anti-Cdc7, anti-phospho-ATR (S1989), anti-phospho-Nbs1 (S343), and anti-phospho-Chk1 (S317) antibodies. β-actin was served as a loading control. The expression of endogenous Cdc7 (Endo-Cdc7) and adenovirally introduced Myc tagged Cdc7 (Myc-Cdc7) is shown. (G) Cdc7 overexpression reduces BrdU incorporation. U2OS cells were infected with Ad-Cdc7 (2.4 × 10⁸ pfu/ml), Ad-Cdc7KD (2.4 × 10⁸ pfu/ml), or Ad-Vec (2.4 × 10⁸ pfu/ml) for 48h, and immunostaining was performed by using antibodies toward BrdU and Myc. U2OS cells treated with UV irradiation (50 J/m²) only were used as a positive control. DAPI was used for nuclear staining. The graph with error bars indicating the standard error from the average is shown in the right panel. Results are presented as range of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
hr) in a dose-dependent manner (Fig. 2C–E, and Supplementary Figure 3). In addition, when Cdc7 was overexpressed, ssDNA (RPA2) accumulation on chromatin and the phosphorylation of Chk1, Chk2, MCM2-S108, and γH2AX were increased during the first 6 hr after HU release (Fig. 2F, Ad-myc-Cdc7 set, 0 to 6 hr). These data confirmed that overexpression of Cdc7 causes DNA lesions (ssDNA and DSB) and activates S-phase checkpoint. Interestingly, we also found that HR DNA repair proteins, RPA2, Mre11, Rad51, and Rad52, were increased on damaged DNA sites (Fig. 2F, 0 to 6 hr). However, non-homologous end-joining (NHEJ) pathway, RPA2 phosphorylation at S4/S8 34, is not involved in Cdc7-induced DNA repair (Fig. 2F). After 6 hr from release, Cdc7 overexpression reduced the phosphorylation of H2AX, checkpoint proteins (e.g. Chk1 and Chk2), and the HR proteins (e.g. RPA2 and Rad51) on damaged DNA (Fig. 2F, Ad-myc-Cdc7 set, 9 to 12 hr). These results suggest that overexpression of Cdc7 initially activates checkpoint and delays cell cycle progression, and it then induces HR repair and recovery from replication stress.

Figure 2. Aberrant Cdc7 activates S-phase checkpoint and homologous recombination (HR) DNA repair during recovery from replication stress. (A) Cdc7 overexpression reinforces cancer cells survival in response to HU treatment. U2OS cells infected with adenovirus encoding GFP (Mock, Ad-Vec, 7.2 × 10⁸ pfu/ml) or Myc-Cdc7 (Ad-Cdc7, 2.4 or 7.2 × 10⁸ pfu/ml) were incubated for 24 hours and then the cells were treated by hydroxyurea (HU, 5 mM). After 24 hour treatment, cell viability was determined. (B) Treatment protocol for HU release experiment. U2OS cells infected with Ad-Cdc7 (2.4 or 7.2 × 10⁸ pfu/ml) or Ad-GFP (7.2 × 10⁸ pfu/ml) for 24 hours were treated with 2 mM HU for 24 hours, and the treated cells were released into normal medium for the time indicated. C and D. Cdc7 overexpression delays cell cycle progression after HU treatment. Infected U2OS cells were treated with 2 mM HU for another 24 hours, released from the treatment, and collected at indicated time. FACS analysis was performed to demonstrate cell cycle distribution (C) and the percentages of cells in G1/S (3 hr), S (6 hr) and G2/M (9 hr) phase are shown in (D). E and F. Cdc7 overexpression activates S-phase checkpoint, delays cell cycle progression, and promotes HR repair after HU treatment. U2OS cells infected with Ad-GFP or Ad-myc-Cdc7 (7.2 × 10⁸ pfu/ml) were released from HU treatment (2 mM for 24 hrs). The cell lysates from different time points after the treatment were collected as whole cell extract (WCE) and were also used to separate the Triton-insoluble chromatin-containing fraction (chromatin). The samples were analyzed by immunoblotting. Equal amounts of input protein were subjected to immunoblotting using anti-cyclin E, anti-cyclin A, anti-cyclin B1, anti-cyclin D1, anti-Histon3-pS10, anti-Chk1-pS317, anti-Chk2-pT68, anti-MCM2-pS108, anti-γH2AX-pS139, anti-RPA2, anti-Mre11, anti-Rad51, anti-Rad52, and anti-RPA2-pS4/8 antibodies. β-actin and Ku70 were served as a loading control. The number represents the band intensity normalized against β-actin or Ku70. Histograms of anti-Chk1-pS317, anti-Chk2-pT68, and anti-γH2AX-pS139 level are shown in the right panel.
Overexpression of Cdc7 promotes HR DNA repair and replication restart under replication stress. We next proved whether upregulated Cdc7 promotes recovery and HR DNA repair after fork stalling. We first performed the HR DSB repair assay using I-SceI endonuclease to introduce genomic DSBs in U2OS cells that are transfected by DR-GFP reporter containing two mutated GFP cassettes, ScGFP and iGFP. The efficiency of HR repair was measured 48 hours later by scoring the percentage of GFP-positive cells in the I-SceI-transfected cells. The percentage of GFP-positive cells was significantly higher in Cdc7-overexpressing cells compared with the cells without Cdc7 overexpression, and this increase was inhibited by overexpression of Cdc7KD mutant (Fig. 3A). This data indicates that Cdc7 overexpression stimulates HR DNA repair. Since Cdc7 kinase is crucial to the initiation of DNA replication, we analyzed whether Cdc7 overexpression promotes replication restart after HU treatment by using replication foci analysis. U2OS cells were pulse-labeled with 5-chlorodeoxyuridine (CldU), treated with HU for 24 hr, and pulse-labeled with 5-iododeoxyuridine (IdU) as indicated (Fig. 3B). Overexpression of Cdc7 but not Cdc7KD significantly increased cell numbers of only labeled IdU, which presents the newly-entered S phase cells (Fig. 3C). The results indicate that overexpression of Cdc7 promotes HR DNA repair, replication restart, and new origin firing during recovery from replication stress.

The phosphorylation of HSP90Ser164 by Cdc7-Dbf4 is required for the maintenance of ATM/ ATR-mediated checkpoint activation and HR DNA repair under replication stress. Since Cdc7-Dbf4 is active under replication stress and plays a role in ATM/ATR checkpoint and HR DNA repair, we attempted to identify the targets of human Cdc7-Dbf4 under replication stress by using a phosphoproteomic experiment. By phosphoproteome analysis, we acquired 831 unique phosphopeptides corresponding to 1209 quantified phosphosites on 462 phosphoproteins including TOP2A, MCM2, Cdt1, HSP90 (Table S1-S3). We indeed found that the HSP90-HCLK2 complex was phosphorylated after UV treatment (Fig. 4A). To validate HSP90 is a direct substrate of Cdc7-Dbf4 kinase, we performed in vitro kinase assay using different approaches. In vitro kinase assays showed that HSP90 is phosphorylated (about 95 kDa) when His-HSP90 was immunoprecipitated from 293T cells as an in vitro substrate (Fig. 4B, left) and GST-MCM2 (1-169 aa) as a control substrate. Consistently, HSP90 phosphorylation was dramatically inhibited when Cdc7 inhibitor (PHA767491) was used (Fig. 4B, left). We also confirmed that Cdc7-Dbf4 directly phosphorylates HSP90 using recombinant Cdc7-Dbf4 as a kinase and recombinant His-HSP90 as a substrate (Fig. 4B, right). In vitro kinase assay showed that the N-domain (1-221 residues) and C-domain (629-732 residues) of HSP90α were phosphorylated by Cdc7-Dbf4 (Fig. 4C). Furthermore, we identified the Cdc7-Dbf4 phosphorylation sites of HSP90α at S164 (Fig. 4D) and S263 (Supplementary Figure 4) by mass spectrometry. The phosphorylation site of HSP90α at Ser164 was confirmed by the introduction of HSP90α-S164A mutation (Fig. 4E). To prove HSP90 phosphorylation at Ser164 in vivo, we generated a phospho-specific antibody for S164 phosphorylation of HSP90α, and the specificity of affinity-purified antibody was confirmed (Supplementary Figure 5). To verify the function of HSP90α phosphorylation by Cdc7-Dbf4 in checkpoint regulation in vivo, we repeated the HU release experiment shown in Fig. 2B. We found that the S164 phosphorylation of HSP90α was increased during 0 to 3 hr and decreased after 6 hr (Fig. 4F). Taken together, these results confirmed that Cdc7-Dbf4 phosphorylates HSP90 at Ser164 in vitro and in vivo. Intriguingly, we also observed that the trend in Rad18 phosphorylation at S434 is similar to the one in HSP90α S164 phosphorylation (Fig. 4F). Cdc7-Dbf4 phosphorylates Rad18 to guide DNA polymerase η to sites of stalling fork and to activate Rad18 to mono-ubiquitinate PCNA, which promotes TLS. This result indicates that increased Cdc7-Dbf4 also promotes DNA damage tolerance under replication stress through activating TLS.

Since HSP90-HCLK2 complex is an important activator to ATR signaling, we examined whether the S164 phosphorylation of HSP90α regulates the ATM/ATR activation. We found that HSP90α-S164A mutant decreased the stability of the ATM/ATR checkpoint complex including ATM, ATR, HCLK2, TTT1, and MRN complex and attenuated the ATM/ATR signaling upon UV exposure (Fig. 4G). Consistently, overexpression of HSP90 increased the HR DNA repair caused by Cdc7, but the S164A mutant inhibited the HR DNA repair (Fig. 4H). These results indicate that the phosphorylation of HSP90-Ser164 by Cdc7-Dbf4 is required for the maintenance of ATM/ATR-mediated S-phase checkpoint activation, HR DNA repair, and the stability of ATM/ATR signaling component proteins under replication stress.

The phosphorylation of HSP90-Ser164 by Cdc7-Dbf4 is required for the stability of ATR-HSP90-HCLK2-Mre11 complex that supports HR DNA repair and recovery under replication stress. We further confirmed whether Cdc7-Dbf4 regulates ATM/ATR signaling via direct stabilization of ATR/ATM activating auxiliary proteins, HCLK2, HSP90, and Mre11. We first confirmed that HCLK2 is required for ATR signaling activation, including the phosphorylation of Chk1 at S317 and Ddb4 at S539 (Supplementary Figure 6). Consistently, Cdc7-Dbf4 indeed interacts with HSP90 (Fig. 5A) and Mre11 (Fig. 5B), and HCLK2 (Fig. 5C) shown by reciprocal co-immunoprecipitation. The association with HCLK2 is enhanced by UV, H2O2, or HU treatment (Fig. 5D). Cdc7-Dbf4 and HSP90 interact with the N- and C-terminal domain of HCLK2 (Supplementary Figure 7). We found that the protein level of HSP90, HCLK2, and ATR was increased in Cdc7-overexpressing cells and decreased when Cdc7 was knocked-down (Fig. 5E). These results indicate that overexpression of Cdc7 promotes HR DNA repair, replication restart, and new origin firing during recovery from replication stress.

The phosphorylation of HSP90-Ser164 by Cdc7-Dbf4 is required for the stability of ATR-HSP90-HCLK2-Mre11 complex that supports HR DNA repair and recovery under replication stress. We next proved whether upregulated Cdc7 promotes recovery and HR DNA repair after fork stalling. We first performed the HR DSB repair assay using I-SceI endonuclease to introduce genomic DSBs in U2OS cells that are transfected by DR-GFP reporter containing two mutated GFP cassettes, ScGFP and iGFP. The efficiency of HR repair was measured 48 hours later by scoring the percentage of GFP-positive cells in the I-SceI-transfected cells. The percentage of GFP-positive cells was significantly higher in Cdc7-overexpressing cells compared with the cells without Cdc7 overexpression, and this increase was inhibited by overexpression of Cdc7KD mutant (Fig. 3A). This data indicates that Cdc7 overexpression stimulates HR DNA repair. Since Cdc7 kinase is crucial to the initiation of DNA replication, we analyzed whether Cdc7 overexpression promotes replication restart after HU treatment by using replication foci analysis. U2OS cells were pulse-labeled with 5-chlorodeoxyuridine (CldU), treated with HU for 24 hr, and pulse-labeled with 5-iododeoxyuridine (IdU) as indicated (Fig. 3B). Overexpression of Cdc7 but not Cdc7KD significantly increased cell numbers of only labeled IdU, which presents the newly-entered S phase cells (Fig. 3C). The results indicate that overexpression of Cdc7 promotes HR DNA repair, replication restart, and new origin firing during recovery from replication stress.
under replication stress, which is accomplished by binding/stabilizing ATR-HSP90-HCLK2-Mre11 complex through HSP90-S164 phosphorylation.

**Clinical significance of Cdc7-ATR-HCLK2 complex and the phosphorylation of HSP90-S164 in oral squamous cell carcinoma (OSCC).** We tried to link the relationship between Cdc7-Dbf4 and ATR-HSP90-HCLK2 complex in the aspect of clinical patients. Our results showed that most of oral cancer-derived cells had a higher protein level of Cdc7-Dbf4 and ATR-HSP90-HCLK2 complex than normal human oral keratinocytes (HOK) (Fig. 6A), suggesting that Cdc7-Dbf4 and ATR-HSP90-HCLK2 complex are overexpressed in Oral Squamous Cell Carcinoma (OSCC). Encouragingly, we found that the expression of
Figure 4. Cdc7-Dbf4 phosphorylates HSP90α at Ser-164 and the phosphorylation is required for the activation of ATM/ATR-mediated checkpoint and HR repair. (A) HSP90α is a phosphorylated protein upon UV treatment. The plasmid encoding His-HSP90 was transfected into 293T cells followed by treatment with UV (50 J/m²). The cell lysates were collected and analyzed by immunoprecipitation and immunoblotting. Equal amounts of input protein were subjected to immunoblotting using anti-phospho-Serine/anti-phospho-Threonine (p-S/T), anti-Dbf4, anti-HCLK2, anti-HSP90, and anti-ATR-pT1989 antibodies. β-actin was served as a loading control. The phosphorylation of ATR-T1989 was a positive control to UV treatment (right). (B) Cdc7-Dbf4 phosphorylates HSP90α in vitro. In vitro kinase assay was performed using 293T cells that is transiently transfected with FLAG-tagged Dbf4 and Cdc7 plasmid. Anti-FLAG immunoprecipitates were incubated with the pulled-down His-HSP90α or GST-MCM2 (aa1-169) as a positive control in the presence of [γ-32P]ATP at 30 °C for 40 mins. Before incubation, each set of immunoprecipitates was treated with or without PHA-767491. Phosphorylation of HSP90α and the input of immunoprecipitated HSP90α were shown by autoradiogram (left) and Western blotting (bottom), respectively. Recombinant Cdc7-Dbf4 was also used to incubate with recombinant His-HSP90α or GST-MCM2 (aa1-169) in the presence of [γ-32P]ATP. Phosphorylation of HSP90α and the input of GST-MCM2 and recombinant HSP90α were shown by autoradiogram (middle) and Coomassie Blue-stained gel (right), respectively. (C) Cdc7-Dbf4 phosphorylates N- and C-terminal domain in HSP90α in vitro. In vitro kinase assay was performed using 293T cells that is transiently transfected with FLAG-tagged Dbf4 and Cdc7 plasmid as described in (B). Cdc7-mediated phosphorylation of HSP90α fragments was revealed by an 32P autoradiogram (left), and relative input for the His-fused HSP90α fragments is shown by a Coomassie Blue-stained gel (right). D and E. Cdc7-Dbf4 phosphorylates HSP90α at Ser 164. (D) Purified Cdc7-Dbf4 and HSP90α were incubated at 30 °C for 40 mins, then the mixture was collected after in-gel digestion and used in MS/MS spectrum analysis. NanoLC−nanoESI-MS/MS analysis was performed on a nanoAcquity system. MS/MS spectrum shows [M+2H]2⁺ (m/z 779.65) ion of the peptide HNDDEQYAWE[pS]SAGGSFTVR from the HSP90α protein, which is a phosphorylated peptide. (E) In vitro kinase assay was performed. Anti-FLAG immunoprecipitates were incubated with the purified His-HSP90α fragment (1-221) WT or S164A mutant in the presence of [γ-32P]ATP at 30 °C for 40 mins. The phosphorylation of HSP90α fragments was revealed by an 32P autoradiogram (top), and relative input for the His-HSP90α fragments is shown by a Coomassie Blue-stained gel (bottom). (F) Cdc7 overexpression promotes the recovery from HU treatment by phosphorylating HSP90α-S164 and Rad18-S434 in vivo. U2OS cells infected with Ad-GFP or Ad-myc-Cdc7 (7.2×10⁸ pfu/ml) were released from HU treatment (2 mM for 24 hrs). The cell lysates from different time points after the treatment were collected as whole cell extract. The samples were analyzed by Western blotting using the indicated antibodies. (G) HSP90α-S164 phosphorylation is required for the stability and activation of the ATM/ATR signaling complex upon UV exposure. U2OS cells transfected with the plasmid encoding HSP90α-WT and S164A mutant were exposed to UV (100 J/m²) and incubated for 3 hours. Cell lysates were prepared and immunoblotting was performed...
Cdc7-Dbf4 corresponds with the expression of HSP90, HCLK2, TTI1, and ATR (Fig. 6A). To link their clinical significance, 154 tumor tissues from OSCC patients were used to determine the expression pattern by immunohistochemistry (IHC) analysis. The clinicopathological characteristics in 154 patients are shown in Table S4. The multivariate Cox analysis showed that cigarette smoking, differentiation, and lymph node metastasis are independent risk factors to predict poor outcome of OSCC patients (Table S5), which is similar to our recent study on OSCC. Subsequently, our results indicated that the expression of Cdc7 is significantly positively correlated with HCLK2 (P = 0.001) and ATR (P = 0.037); it has the same trend with the expression of HSP90 (Fig. 6B). To further link the clinical significance of the HSP90-S164 phosphorylation in cancer tissues, 20 samples of tumor tissues and 3 benign tissues from OSCC patients were used to determine the pattern of HSP90-S164 phosphorylation by IHC analysis. The positive staining was observed in the majority of OSCC tumor tissues (18/20, 90.0%), whereas absent staining was observed in benign tissue (Fig. 6C). These results indicate that the level of Cdc7-Dbf4 is correlated with the one of ATR; the phosphorylation of HSP90 at S164 by Cdc7-Dbf4 is overexpressed and detected in OSCC patients.

**Discussion**

Human Cdc7-Dbf4 remains active and functions as an upstream regulator to monitor S-checkpoint signaling in responses to replication stress. Our previous finding suggests that increased Cdc7-Dbf4 inhibits genotoxin-induced apoptosis to enhance the survival of oral cancer cells upon DNA damage. Therefore, Cdc7-Dbf4 may perform its kinase activity to phosphorylate its downstream substrates to regulate checkpoint function to enhance the survival of cancer cells under replication stress. In this study, we provided the compelling evidence that Cdc7-Dbf4 interacts with HCLK2-HSP90-Mre11 complex and phosphorylates HSP90-S164 to enhance ATR/ATM checkpoint signaling, HR DNA repair, and checkpoint recovery, which enhances replication stress tolerance for the survival of cancer cells.

We identified HSP90 as a downstream substrate of Cdc7-Dbf4 to enhance ATM/ATR-mediated checkpoint and DNA repair upon replication stress. HSP90 is a molecular chaperone with more than 200 identified client proteins, including ATM, Mre11/Rad50/Nbs1 complex, HCLK2-TTI1/2 complex, BRCA1, and REV-1 that are accountable for the activation of ATR signaling, DNA repair, or trans-lesion synthesis (TLS). HSP90 also acts as a facilitator of tumor progression, morphological evolution, and treatment-resistant phenotypes. We found that the human Cdc7-Dbf4 kinase phosphorylates HSP90-S164 that determines the stability of HSP90 and the association with its clients in the ATM/ATR signaling. Consistently, the chaperone function of HSP90 is regulated by post-translational modification. For example, the phosphorylation of HSP90 at Thr-22 by CK2 is essential for the binding of HSP90 with its cochaperone. The phosphorylation of C-terminus HSP90 determines the choice of its binding to different co-chaperones of HSP90 that decides the folding or degradation of its client proteins. However, the issue that whether the phosphorylation of HSP90 by Cdc7-Dbf4 regulates the ATM-mediated signaling through other phosphorylation sites will need further investigation.

We further found that highly-upregulated Cdc7 promotes not only HR DNA repair but fork recovery, replication restart, and TLS during replication stress, which enhances DNA damage tolerance and cell survival in cancer. Consistently, substantial evidences showed that Cdc7-Dbf4 participates in the S-phase checkpoint recovery and TLS from fork arrest upon replication stress. Upon removal of replication stress, Cdc7-mediated phosphorylation is required for S-phase recovery and fork stability. It is possible that Cdc7-Dbf4 performs its kinase activity to phosphorylate its unknown substrates to regulate checkpoint function and resume replication...
Figure 5. The phosphorylation of HSP90-Ser164 by Cdc7-Dbf4 is required for the stability of ATR-HSP90-HCLK2-Mre11 complex that supports HR DNA repair and recovery under replication stress. (A) Cdc7-Dbf4 interacts with HSP90α. The plasmids encoding Flag-tagged Dbf4 was cotransfected with plasmid encoding His-HSP90α into 293T cells. Immunoprecipitation and immunoblotting were performed as indicated antibodies. (B) Cdc7-Dbf4 interacts with Mre11. 293T cells were co-transfected with plasmids encoding Flag-tagged Cdc7, Myc-tagged Dbf4, and Mre11 followed by co-immunoprecipitation with anti-Cdc7 and anti-Mre11 antibody, respectively. Immunoprecipitation and immunoblotting were performed as indicated. (C) Cdc7-Dbf4 interacts with HCLK2. The plasmids encoding Myc-Cdc7, Flag-tagged Dbf4, or Myc-tagged Dbf4 were cotransfected with plasmid encoding Flag-HCLK2 into 293T cells. Immunoprecipitation and immunoblotting were performed as indicated. (D) The association between Cdc7-Dbf4 and HCLK2 increases in response to DNA damage stress. The plasmids encoding Myc-tagged Dbf4 were cotransfected with plasmid encoding Flag-HCLK2. The transfected cells were treated with or without UV radiation (100 J/m²), hydrogen peroxide (200 µM), or HU (2 mM). Immunoprecipitation was performed as indicated. (E) Cdc7 is important for the stability of HSP90, HCLK2, and ATR proteins. For overexpression experiment, U2OS cells was infected with Ad-Cdc7 using different viral titers (0.6, 3.6, or 7.2 × 10⁸ pfu/ml) or Ad-GFP control (3.6 × 10⁸ pfu/ml). For knocking-down experiment, Cdc7 expression was inhibited by Cdc7-shRNA transfection. Immunoblotting were performed using the indicated antibodies. (F) The level of Cdc7 does not affect the gene expression of HSP90 and HCLK2 in RNA level. Cells were infected with Ad-Cdc7 using different viral titers (0.6, 3.6, or 7.2 × 10⁸ pfu/ml) for overexpression or transfected with Cdc7-shRNA for down-regulation. Afterwards, cells were collected and extracted to obtain RNA that was used to reverse-transcribe to cDNA. Quantitative real-time PCR analysis or DNA gel electrophoresis showed the RNA level of HSP90. The error bars shown in the panel represent the standard deviation from three different experiments. (G) The activity of Cdc7-Dbf4 is required for the binding between HSP90 and checkpoint proteins including ATR, HCLK2, MRN, and Cdc7-Dbf4. 293T cells were transfected with plasmid encoding His-HSP90α and treated with or without PHA-767491 (5 µM) for 3 h. Immunoprecipitation and immunoblotting were performed using the indicated antibodies. (H) The activity of Cdc7-Dbf4 is required for chromatin-unbound Mre11 phosphorylation and the recruitment of HR repair proteins from upon UV stress. U2OS cells were treated with PHA-767491 (0.3 or 3 µM) for 6 h and with or without UV radiation (100 J/m²) followed by recovery for 2 h. The soluble and chromatin fraction were analyzed by immunoblot using the indicated antibodies. (I) HSP90-S164 phosphorylation is required for the interaction of HSP90 and checkpoint proteins including ATR, ATM, HCLK2, Rad50, Chk1 and Chk2. 293T cells were transfected with plasmids encoding His-tagged HSP90 WT or S164A. Immunoprecipitation and immunoblotting were performed using the indicated antibodies.
restart and S phase progression. For instance, Cdc7-Dbf4 may facilitate checkpoint recovery and replication restart by releasing phosphorylated Rad9 from DNA damage sites in yeast\(^6\) and by promoting the dissociation of ATR/ATM-dependent phosphorylated Mre11 from chromatin (Fig. 5H), which suggests that MRN dissociation from DNA is involved in the checkpoint recovery following DSB repair. Taken together, we suggest that overexpression of Cdc7 not only causes more DNA lesions to activate checkpoint and HR DNA repair during the early stage of replication stress but also triggers TLS and replication restart as a compensatory mechanism for the survival of cancer cells.

Cancer cells rewire DNA damage response and induce DNA repair to overcome replication stress barriers for tumor progression, which also is a major cause of radio- or chemo-resistance\(^5\)\(^,\)\(^6\). In present study we present a novel function of excess Cdc7-Dbf4 in overriding replication stress to promote cancer cell survival and tumorigenesis by the phosphorylation of HSP90 at S164 that enhances the ATR/ATM-mediated signaling and HR DNA repair. Cancer cells bearing checkpoint/repair-deficiency or oncogene-induced replication stress paradoxically increase ATR-Chk1 signaling expression to tolerate the stress for proliferation and survival\(^5\)\(^,\)\(^6\). In addition, HSP90 is often

---

**Figure 6.** Clinical significance of Cdc7-ATR-HCLK2 complex and the phosphorylation of HSP90α at Ser-164 in oral squamous cell carcinoma (OSCC). (A) Aberrant expression of Cdc7-Dbf4 and ATR-HSP90-HCLK2 complex in oral cancer cell lines. The extracts of oral cancer cell lines were immunoblotted with indicated antibodies and antibody to actin as a loading control. (B) Clinical significance of interaction between Cdc7-Dbf4 and ATR-HSP90-HCLK2 complex in OSCC patients. The Spearman correlation coefficients were used to assess the associations between Cdc7, ATR, HCLK2, and HSP90 protein levels, which are categorized into no available, low, median, and strong according to the scores of IHC staining. (C) Immunohistochemical analysis of HSP90 phosphorylation at S164 in OSCC patients. Representative immunohistochemical analysis of HSP90 phosphorylation at S164 was performed by using paraffin-embedded sections of OSCC and benign oral tissue. Microscopic magnification was ×400. (D) Model of Cdc7-Dbf4-mediated phosphorylation events in promoting replication stress tolerance in cancer. In this study, we present the potential mechanisms that aberrant Cdc7-Dbf4 enhances DNA damage tolerance in cancer via regulating replication restart, translesion synthesis (TLS), and ATR/ATM-mediated checkpoint-HR signaling. Aberrant Cdc7-Dbf4 induces DNA lesions formation that induces replication stress and activates ATR/ATM-mediated checkpoint and HR DNA repair, and it further induces checkpoint recovery and replication restart to promote the recovery from replication stress. Cdc7-Dbf4 interacts with the ATR-HCLK2-HSP90-MRE11 complex and determines the protein stability of the complex by phosphorylating HSP90 at S164. The phosphorylation of HSP90-S164 is required for the stability and the function of ATR/ATM signaling complex cascades, which includes HR DNA repair and the recovery from replication stress. Cdc7-Dbf4 also enhances TLS and DNA damage tolerance by phosphorylating Rad18 at S434. These results illustrate that Cdc7-Dbf4 rewires different functions in DNA damage tolerance to overcome replication stress, which causes genome instability to promote tumorigenesis.
exploited by cancer cells during tumor progression to promote survival and metastasis by binding its oncprotein clients, such as AKT and ATR. Thus, it isn’t surprising that ATR kinase and HSP90 are selected to be promising targets of anti-cancer drug. For example, HSP90 inhibitor, geldanamycin, 17-AAG, 17-DMAG, ganetespib, or NVP-AUY922, is currently being explored in combination therapy or clinical trials in various human malignancies. However, several mechanisms of drug resistance for HSP90 inhibitor treatment were found. Our new finding will provide valuable information for a specific type of adjuvant combination therapy that combines the inhibitors of Cdc7, HSP90, and/or ATR to block DNA synthesis and exploit defects in DNA repair/checkpoint of tumor cells. Cdc7-Dbf4 kinase also is an excellent target for therapeutic strategies that not only block DNA synthesis at the beginning but also sensitize cancer cells to DNA damage by targeting HSP90/ATR/ATM, which may promise a promising approach to enhance the therapeutic effect of radiation or chemotherapy.

In summary, this study demonstrates that human Cdc7-Dbf4 plays multiple roles in replication stress tolerance (Fig. 6D). Aberrant Cdc7-Dbf4 induces replication stress that causes DNA lesions and activates the S-phase ATM/ATR checkpoint and HR repair. Cdc7-Dbf4 interacts and stabilizes the HCL2K-HSP90-Mre11 complex by phosphorylating HSP90 at S164, which are required for the activation of ATM/ATR signaling cascade. Cdc7-Dbf4 rewrites and coordinates ATM/ATR-mediated signaling, HR DNA repair, TLS, and replication restart to promote recovery from replication stress. This study presents a novel function of Cdc7-Dbf4 in overriding replication stress to activate ATM/ATR signaling, and it opens a new direction to overcome replication stress tolerance in the defects in DNA repair/checkpoint in clinical by using a combination cancer therapy that combines the inhibitors of Cdc7, HSP90, and/or ATR.

Methods

Patients and clinical sample. A total of 154 cases of OSCC were chosen for IHC analysis based on availability of archival human oral tissue blocks from diagnostic resection specimens in the Departments of Pathology at Mackay Memorial Hospital, Taipei, Taiwan. The informed consent was obtained from each patient before the specimen was collected into the archive. The experiment was performed with approval from the Institutional Review Board (IRB number: 13MHHIS188). The main clinical characteristics of the 154 patients selected for this study are detailed in Table S1. All experiments were performed in accordance with relevant guidelines and regulations.

Cell culture and cell treatment. U2OS, 293T, and oral cancer cell lines were cultured in medium as described previously. For HU release experiment, U2OS cells infected with Ad-Cdc7 (2.4 or 7.2 x 10⁹ pfu/ml) or Ad-GFP for 24 h were synchronized with 2 mM HU for 24 hours prior to collection. The cells were collected at indicated time after HU release and were examined by FACS analysis or Western blot.

Western blot analysis and antibodies. Western blot analysis was performed as described before. Antibodies to human HCL2K were generated by immunizing rabbits with using OVA-conjugated peptide (RIRRTQQLSKGPRQPGPAG). Antibodies to human HSP90-pS164 and Rad18-pS434 were generated by immunizing rabbits with OVA-conjugated peptide DDEQYAWESG[S]AGGS and IQFELSS[S]ESDS, respectively. Antibodies to human Dbf4 and Dbf4 Ser-359 phospho-specific were generated as described previously. Antibodies used in this study were purchased as indicated: Antibody to Cdc7 (DCS-341) from Thermo Scientific; Rad52, cleaved Caspase-3 (Asp175, SA1E), phospho-Chk1 (S317), phospho-Chk2 (T68), phospho-NBS1(S343), p53, and phospho-p53 (S46) antibodies from Cell Signaling Technology; Cdc6, Cdc45, cyclin A, cyclin D1, PCNA, and Ku70 from Santa Cruz Biotechnology, Inc.; ATR antibody from Abnova; phospho-ATR(T1989) antibody from MyBioSource; HSP90α and His-tag antibodies from Abcam; Mre11, RPA1, and RPA2 antibodies from Calbiochem Merck; Myc (9E10), Actin, γ-H2AX (Ser139), Rad50, Rad51 phospho-ATM (S1981), V5-Tag, phospho-serine, phospho-threonine, and phospho-Histone3 (S10) from Millipore; Phospho-MCM2 (S108), Phospho-MCM2 (S53), Phospho-MCM2 (S40/41), and Phospho-RPA2 (S4/S8) from Bethyl Laboratories; BrdU, MCM2, cyclin B1, and cyclin E from BD Biosciences; FLAG (M2) from Sigma-Aldrich; Actin, ATM, Cdt1, NBS1 and GAPDH from GenTex.

Adenovirus construction and infection. Adenoviruses encoding GFP (Ad-Vec) and human Cdc7 (Ad-Cdc7) were generated and purified by using the AdEasy system and as described previously. Large scale purification of adenovirus from 293 cells was performed by CsCl density gradient centrifugation. The concentration of purified virus was measured OD₅₉₀ using the equation 1OD₅₉₀ = 10¹² pfu/ml. Recombinant adenoviruses encoding Cdc7KD (D196N) was a gift from Dr. Xiaohua Wu (The Scripps Research Institute, La Jolla, CA, USA).

Cell viability and survival assay. Cell viability assay was examined using the CellTiter 96 AQueous One Solution Cell Proliferation Assay Kit (Promega, USA) according to the manufacturer's recommendations. Percentage of cell viability was analyzed and normalized against the untreated controls.

Comet Assay. The neutral comet assay was performed by using the comet assay kit (4250-050-K; Trevigen, Gaithersburg, MD) according to the manufacturer's recommendations with minor modification. Briefly, U2OS were stained with SYBR Green (Trevigen; 1:10000 dilution), visualized by fluorescence microscope, and analyzed. Comet tails are formed in the cells carrying DSBs. The relative length and intensity of SYBR green-stained nuclei were stained with SYBR Green (Trevigen; 1:10000 dilution), visualized by fluorescence microscope, and analyzed.

Fluorescence activated cell sorting (FACS) analysis. Cells were washed twice with PBS (2.7 mM KCl, 1.0 mM KH₂PO₄, 137 mM NaCl, 10 mM Na₂HPO₄, pH 7.4), trypsinized, followed by washing once with cold PBS. Cells were fixed with ice cold 70% ethanol overnight at 4°C and stained with propidium iodide solution which...
containing 2 mM MgCl₂, 1% Triton X-100, 100 ng/ml RNase A and 0.1 mg/ml propidium iodide (Sigma-Aldrich, St Louis, MO, USA). The labeled cells were analyzed with a FACSCalibur flow cytometer (Becton-Dickinson Biosciences, Mansfield, MA, USA) using CELLQUEST software (Becton-Dickinson).

**Immunofluorescence staining.** The immunofluorescence staining was determined as described previously with minor modifications. U2OS cells cultured in glass slides were infected with Ad-Myc-Cdc7 (1.2 × 10⁶ pfu) or Ad-Vec for 48 h. The cells were fixed in 3.7% formaldehyde in PBS for 10 min at room temperature and permeabilized with 0.1% Triton X-100 for 5 min. After blocked in 3% BSA, the cells were incubated with primary antibody 1 h at 37°C and then with the anti-mouse fluorescence-labeled secondary antibody 1 h at room temperature. DNA was stained with 4.6-diamidino-2-phenylindole dilactate (DAPI, Invitrogen). For 5-Bromo-2′-deoxy-uridine (BrdU) incorporation assay, U2OS cells cultured in glass slides were infected with Ad-Myc-Cdc7 (1.2 × 10⁶ pfu/ml) or Ad-Vec for 48 h. U2OS cells infected with Ad-Myc-Cdc7 or Ad-Vec were treated with 30 μM BrdU (Sigma) for 15 min, which could be incorporated into DNA during the S phase, and the cells were blocked with 3.7% paraformaldehyde. Subsequently, the cells were incubated with 2 M HCl for 30 min at 37°C to denature DNA and treated with 0.1 M borate buffer (Na₂B₂O₂, pH 8.5) for 5 min to neutralize the acid. After 3% BSA blocking for 1 h at room temperature, the cells were incubated with mouse anti-BrdU antibody (1:200) or anti-γ-H2AX (1:200) 1 h at 37°C, then with goat anti-mouse DyLight fluorescence-conjugated secondary antibody for 1 hour at RT. The above experimental results were analyzed by an Olympus BX51 fluorescence microscopy.

**Homologous recombination (HR) assay.** HR assay was performed as described previously with minor modification. U2OS cells transfected with DR-GFP were used for HR assay (a generous gift from Dr. Maria Jasim). To examine HR repair, we performed the DSB repair assay using I-SceI endonuclease to introduce genomic DSBs in U2OS cells which are transfected by DR-GFP reporter containing two mutated GFP cassettes, SceGFP and iGFP. To determine the effect of Cdc7 overexpression on efficiency of HR-mediated DSB repair, U2OS (DR-GFP) cells were transfected with I-Sce1 vector only, or co-transfected with pcDNA3-myc-Cdc7 or pcDNA3-myc-Cdc7KD using PolyJet in vitro DNA transfection reagent (SignaGen laboratories). U2OS cells were transfected with eGFP as a positive control, while U2OS (DR-GFP) cells alone were as a negative control. 24 h after transfection, U2OS (DR-GFP) cells were selected positively with puromycin (2 μg/ml) and the cells were incubated for 24 h. Subsequently, flow cytometric analysis was used to determine the percentage of GFP-positive cells.

**DNA replication foci analysis.** DNA replication foci were visualized by incorporation of chlorodeoxyuridine (CluU) and iododeoxyuridine (Idu) into DNA. U2OS cells were labeled with 100 μM CluU (Sigma Chemical Co., St Louis, MO) or 20 μM Idu (Sigma Chemical Co., St Louis, MO) for different time intervals. Primary antibodies for CluU (rat anti-BrdU 1:100; BD Biosciences) and Idu (mouse anti-BrdU 1:100; Abcam) were diluted in 3% BSA and incubated at 37°C for 1 h. The slides were incubated with secondary antibodies (CluU, donkey anti-rat Alexa Fluor 488 [Molecular Probes/Invitrogen]; Idu, goat anti-mouse 594 [Jackson Immunoresearch]) for 1 h. Images were visualized by using a Leica confocal microscope.

**In vitro Kinase Assay.** In vitro kinase assay was performed using 293T cells that is transiently transfected with FLAG-tagged Dbf4 and Cdc7 plasmid or human tagged Cdc7-Dbf4 kinase complex purchased from SignalChem. Anti-FLAG immunoprecipitates or GST-tagged Cdc7-Dbf4 kinase were incubated with the purified His-HSP90 WT, deletion mutants, or GST-MCM2 (aa1-169) as a positive control in Cdc7 kinase buffer (25 mM HEPES pH 7.5, 50 mM NaCl, 10 mM MgCl₂, 1 μM DTT, 10 μM ATP) and in the presence of 10 μCi [γ-32P]ATP and phosphatase inhibitors (10 mM NaF, 50 mM β-glycerophosphate) at 30°C for 40 mins, followed by the addition of SDS-PAGE sample buffer to stop reaction. Phosphorylated radioactive proteins were separated by SDS-PAGE and detected by autoradiography of the dried gels.

**Quantitative reverse transcription-polymerase chain reaction (qRT-PCR).** The qRT-PCR was performed as described previously. The primer sequences used are listed below. Cdc7-F: 5′-CAA AGT GCC CCA ATC AAA CT-3′, Cdc7-R: 5′-TTGGGCAAAGCA GTTAATC-3′; β-actin-F: 5′-CTCTTCCAGCCCTCTCTCCT-3′, β-actin-R: 5′-AGC ACT GTTGTGCGTGTCAG-3′; HSP90α-F: 5′-ATGAAACTGCAGTCTTGTCT; HSP90α-R: TTT TCCATGCGTGTAGTGT. All amplifications were performed in triplicate.

**Immunohistochemistry (IHC) staining.** IHC analysis was performed on an automatic staining machine (BenchMark XT, Ventana Medical Systems, Tucson, AZ, USA) using the iVIEW 3, 3-diaminobenzidine (DAB) detection kit (Ventana Medical Systems). Paraaffin sections (4 μm) containing human of the 110 OSCC tissues were routinely deparaffinized, hydrated, and heated to 95-100°C for 4 min to induce antigen retrieval. After inactive the endogenous peroxidase activity, IHC staining was performed with anti-Cdc7 (Thermo Scientific DCS-341, 1:20). All sections were finally dehydrated with iVIEW copper for 4 min to enhance the signal intensity, then counterstained with hematoxylin, dehydrated, mounted, and observed by a Nikon Eclipse E600 light microscope (Tokyo, Japan). Pictures were acquired using Tissue-Faxs software (TissueGnostics). The staining intensity was estimated in a 4-scored scale (0, Negative staining; 1+, weak; 2+, moderate; 3+, strong intensity). The fraction of stained cells was scored according to the following criteria: Score 0 (no stained or <10% stained cells), Score 1 (11–50% stained cells), Score 2 (51–80% stained cells), Score 3 (>80% stained cells).

**Statistical analysis.** Multivariate Cox proportional hazard model was used to estimate hazard ratios with adjustments for age and gender. We considered a statistical significance if a P-value was <0.05. All data was analyzed using the R statistical software (version 3.1.1). Parametric Student’s t test was used to judge the significance of difference between conditions of interest. The association between Cdc7 protein level (scoring of the IHC
staining) and the quantified clinicopathological features of tumors were examined by χ2 test. Cox proportional hazard regression model and log-rank test was applied for analysis of survival data. In all analysis, a P value of <0.05 was considered as statistically significant (Student’s t test, \(p<0.05\), **p<0.01, and ***p<0.001).

**References**

1. Abraham, R. T. Cell cycle checkpoint signaling through the ATM and ATR kinases. *Genes & development* 15, 2177–2196 (2001).
2. Lee, J. H. & Paull, T. T. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. *Oncogene* 26, 7741–7748 (2007).
3. Rendlewe Danielsen, J. M. et al. HICLK2 is required for activity of the DNA damage response kinase ATR. *The Journal of biological chemistry* 284, 4160–4167, https://doi.org/10.1074/jbc.M808174200 (2009).
4. Flynn, R. L. & Zou, L. ATR: a master conductor of cellular responses to DNA replication stress. *Trends in biochemical sciences* 36, 133–140, https://doi.org/10.1016/j.tibs.2010.09.005 (2011).
5. Houtgraaf, J. H., Versmissen, J. & van der Giessen, W. J. A concise review of DNA damage checkpoints and repair in mammalian cells. *Cardiovascular Revascularization Medicine* 7, 165–172, https://doi.org/10.1016/j.carrev.2006.02.002 (2006).
6. Macheret, M. & Halazonetis, T. D. DNA replication stress as a hallmark of cancer. *Annual review of pathology* 10, 425–448, https://doi.org/10.1146/annurev-pathol-021214-040424 (2015).
7. Gaillard, H., Garcia-Muse, T. & Aguilera, A. Replication stress and cancer. *Nature reviews. Cancer* 15, 276–289, https://doi.org/10.1038/nrc3916 (2015).
8. Branzei, D. & Foiani, M. Maintaining genome stability at the replication fork. *Nat Rev Mol Cell Biol* 11, 208–219, https://doi.org/10.1038/nrm2852 (2010).
9. Krajewska, M. et al. ATR inhibition preferentially targets homologous recombination-deficient tumor cells. *Oncogene* 34, 3474–3481, https://doi.org/10.1038/onc.2014.276 (2015).
10. Bartek, J., Mistrik, M. & Bartkova, J. Thresholds of replication stress signaling in cancer development and treatment. *Nature structural & molecular biology* 19, 5–7, https://doi.org/10.1038/nsmb.2220 (2012).
11. Labib, K. H. do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells? *Genes & development* 24, 1208–1219, https://doi.org/10.1101/gad.193010.110 (2010).
12. Masai, H. & Arii, K. Cdc7 kinase complex: a key regulator in the initiation of DNA replication. *J Cell Physiol* 190, 287–296 (2002).
13. Sasanuma, H. et al. Cdc7-dependent phosphorylation of Mer2 facilitates initiation of yeast meiotic recombination. *Genes & development* 22, 398–410 (2008).
14. Pessoa-Brandao, L. & Scalani, R. A. CDC7/DBF4 functions in the translesion synthesis branch of the RAD6 epistasis group in *Saccharomyces cerevisiae*. *Genetics* 167, 1597–1610 (2004).
15. Day, T. A. et al. Phosphorylated Rad 18 directs DNA Polymerase [eta] to sites of stalled replication. *J Cell Biol* 191, 953–966, https://doi.org/10.1083/jcb.201006043 (2010).
16. Yamada, M. et al. ATR-Chk1-APC/Cdhl1-dependent stabilization of Cdc7-ASK (Dbf4) kinase is required for DNA lesion bypass under replication stress. *Genes & development* 27, 2459–2472, https://doi.org/10.1101/gad.242568.113 (2013).
17. Duncker, B. P. & Brown, G. W. Cdc7 kinases (DDKs) and checkpoint responses: lessons from two yeasts. *Mol Cell 52*, 21–27 (2013).
18. Tsuji, T., Lau, E., Chiang, G. G. & Jiang, W. The role of Dbf6/Drfl1-dependent kinase Cdc7 in DNA damage checkpoint control. *Mol Cell 32*, 862–869 (2008).
19. Lee, A. Y. et al. Dbf4 Is Direct Downstream Target of Ataxia Telangiectasia Mutated (ATM) and Ataxia Telangiectasia and Rad3-related (ATR) Protein to Regulate Intra-S-phase Checkpoint. *The Journal of biological chemistry* 287, 2531–2543, https://doi.org/10.1074/jbc.M111.291104 (2012).
20. Jares, P., Donaldson, A. & Blow, J. I. The Cdc7/Dbf4 protein kinase: target of the S phase checkpoint? *EMBO reports* 1, 319–322 (2000).
21. Tenca, P. et al. Cdc7 is an active kinase in human cancer cells undergoing replication stress. *The Journal of biological chemistry* 282, 208–215 (2007).
22. Takeda, T. et al. A fission yeast gene, him1(+)/dbf1(+), encoding a regulatory subunit for Hsk1 kinase, plays essential roles in S phase as well as in S-phase checkpoint control and recovery from DNA damage. *Molecular and cellular biology* 19, 5353–5357 (1999).
23. Cheng, A. N. et al. Increased Cdc7 expression is a marker of oral squamous cell carcinoma and overexpression of Cdc7 contributes to the resistance to DNA-damaging agents. *Cancer letters* 337, 218–225, https://doi.org/10.1016/j.canlet.2012.05.008 (2013).
24. Trepel, J., Mollapour, M., Giaccone, G. & Neckers, L. Targeting the dynamic HSP90 complex in cancer. *Trends in biochemical sciences* 28, 648–655, https://doi.org/10.1016/j.tibs.2011.07.018 (2012).
25. Quanz, M. et al. Heat shock protein 90alpha (Hsp90alpha) is phosphorylated in response to DNA damage and accumulates in repair foci. *The Journal of biological chemistry* 287, 8803–8815, https://doi.org/10.1074/jbc.M111.230887 (2012).
26. Bonte, D. et al. Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. *Neoplasia* 10, 920–931 (2008).
27. Ananthia, R. W., Vass, V. M. & Borowiec, J. A. Sequential and synergistic modification of human RPA stimulates chromosomal DNA repair. *The Journal of biological chemistry* 282, 35910–35923, https://doi.org/10.1074/jbc.M704645200 (2007).
28. Pierce, A. J., Johnson, R. D., Thompson, L. H. & Jasin, M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. *Genes & development* 13, 2633–2638 (1999).
29. Petermann, E., Orta, M. L., Issaeva, N., Schultz, N. & Halleday, T. Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. *Mol Cell* 37, 492–502, https://doi.org/10.1016/j.molcel.2010.01.021 (2010).
30. Wu, K. Z. et al. DDK-dependent regulation of TOP2a at centromeres revealed by a chemical genetics approach. *Nucleic acids research*, doi:10.1093/nar/gkw628 (2016).
38. Lei, M. et al. Mcm2 is a target of regulation by Cdc7-Dbf6 during the initiation of DNA synthesis. Genes & development 11, 3365–3374 (1997).
39. Ballabeni, A. et al. Human CDT1 associates with CDC7 and recruits CDC45 to chromatin during S phase. The journal of biological chemistry 284, 3028–3036, https://doi.org/10.1074/jbc.M803609200 (2009).
40. Di Virgilio, M., Ying, C. Y. & Gautier, J. PIKK-dependent phosphorylation of Mre11 induces MRN complex inactivation by disassembly from chromatin. DNA repair 8, 1311–1320, https://doi.org/10.1016/j.dnarep.2009.07.006 (2009).
41. Cheng, C. W. et al. Loss of GDF10/BMP3b as a prognostic marker collaborates with TGFBR3 to enhance chemotherapy resistance and epithelial-mesenchymal transition in oral squamous cell carcinoma. Molecular carcinogenesis 55, 499–513, https://doi.org/10.1002/mc.22297 (2016).
42. Collins, S. J. et al. HCKL2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability. Nat Cell Biol 9, 391–401 (2007).
43. Takai, H., Funabiki, N. & Funabiki, H. The EMBO journal 25, 672–681, https://doi.org/10.1038/sj.emboj.7600911 (2006).
44. Muller, P. et al. C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances. Oncogene 32, 3101–3110, https://doi.org/10.1038/onc.2012.314 (2013).
45. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674, https://doi.org/10.1016/j.cell.2011.02.013 (2011).
46. Zheng, L. et al. Polyploid cells rewire DNA damage response networks to overcome replication stress-induced barriers for tumour progression. Nat Commun 3, 815, https://doi.org/10.1038/ncomms1825 (2012).
47. Guo, B., Romero, J., Kim, B. J. & Lee, H. High levels of Cdc7 and Dbf6 proteins can arrest cell cycle progression. Eur J Cell Biol 84, 927–938 (2005).
48. Petermann, E., Woodcock, M. & Heoleday, T. Chk1 promotes replication fork progression by controlling replication initiation. Proceedings of the National Academy of Sciences of the United States of America 107, 16909–16905, https://doi.org/10.1073/pnas.1005031107 (2010).
49. Yoon, S.-W. et al. Meiotic prophase roles of Rec8 in crossover recombination and chromosome structure. Nucleic Acids Research 44, 9296–9314, https://doi.org/10.1093/nar/gkw682 (2016).
50. Frizzi, L. et al. Dbf4-dependent kinase and the Rtt107 scaffold promote Mus81-Mms4 resolvase activation during mitosis. The EMBO journal, doi:10.15252/embj.20164931 (2017).
51. Hanada, K. et al. The structure-specific endonuclease Mus81 contributes to replication restart by generating double-strand DNA breaks. Nature structural & molecular biology 14, 1096–1104, https://doi.org/10.1038/nsmb1307 (2013).
52. Bryant, H. E. et al. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. The EMBO journal 28, 2601–2615, https://doi.org/10.1038/emboj.2009.206 (2009).
53. Allen, C., Ashley, A. K., Hamoa, R. & Nickoloff, J. A. More forks on the road to replication stress recovery. J Mol Cell Biol 3, 4–12, https://doi.org/10.1093/jmcb/mjq049 (2011).
54. Costantino, L. et al. Break-induced replication repair of damaged forks induces genomic duplications in human cells. Science (New York, N.Y.) 343, 88–91, https://doi.org/10.1126/science.1241321 (2011).
55. Carr, A. M. & Lambert, S. Replication stress-induced genome instability: the dark side of replication maintenance by homologous recombination. Journal of molecular biology 425, 4733–4744, https://doi.org/10.1016/j.jmb.2013.04.023 (2013).
56. Hicks, W. M., Kim, M. & Haber, J. E. Increased mutagenesis and unique mutation signature associated with mitotic gene conversion. Science (New York, N.Y.) 329, 82–85, https://doi.org/10.1126/science.1191125 (2010).
57. Irrazi, I. et al. Recovery of arrested replication forks by homologous recombination is error-prone. PLoS genetics 8, e1002976, https://doi.org/10.1371/journal.pgen.1002976 (2012).
58. Jones, D. R., Prasad, A. A., Chan, P. K. & Duncker, B. P. The Dbf4 motif C zinc finger promotes DNA replication and mediates resistance to genotoxic stress. Cell cycle (Georgetown, Tex.) 9, 2018–2026 (2010).
59. Vaziri, C. & Masai, H. Integrating DNA replication and recombination in mammalian cells. Cell division 7, 22, https://doi.org/10.1186/2048-0387 (2012).
60. Furuya, K. et al. DDK phosphorylates checkpoint clamp component Rad9 and promotes its release from damaged chromatin. Mol Cell 40, 606–618, https://doi.org/10.1016/j.molcel.2010.01.026 (2010).
61. Carle, T. et al. DNA damage response as a candidate anti-cancer barrier in early human tumourigenesis. Nature 434, 864–870 (2005).
62. Whitesell, L. & Lindquist, S. L. HSP90 and the chaperoning of cancer. Nature reviews. Cancer 5, 761–772, https://doi.org/10.1038/nrc1716 (2005).
63. Weber, A. M. & Ryan, A. J. ATM and ATR as therapeutic targets in cancer. Pharmacology & Therapeutics 149, 124–138, https://doi.org/10.1016/j.pharmthera.2014.12.001 (2015).
64. Galdino, D. T., Ofchinava, S. O., Patel, P. D. & Chiosis, G. Selective targeting of the stress chaperone as a therapeutic strategy. Trends in pharmacological sciences 35, 592–603, https://doi.org/10.1016/j.tips.2014.09.001 (2014).
65. Proia, D. A. et al. Preclinical activity profile and therapeutic efficacy of the Hsp90 inhibitor ganetespib in triple-negative breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 20, 413–424, https://doi.org/10.1158/1078-0432.ccr-13-2166 (2014).
66. Piper, P. W. & Millson, S. H. Mechanisms of Resistance to Hsp90 Inhibitor Drugs: A Complex Mosaic Emerges. Pharmaceuticals 4, 1–15, https://doi.org/10.3390/ph4111001 (2011).
67. Gaspar, N. et al. Acquired resistance to 17-allylamino-17-demethoxygalenamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer research 69, 1966–1975, https://doi.org/10.1158/0008-5472.can-08-3131 (2009).
68. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921, https://doi.org/10.1038/nature03445 (2005).
69. Cheng, C. W. et al. Overexpression of Lon contributes to survival and aggressive phenotype of cancer cells through mitochondrial complex I-mediated generation of reactive oxygen species. Cell death & disease 4, e681, https://doi.org/10.1038/cddis.2013.204 (2013).
70. Luo, J. et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2, 1236–1247, https://doi.org/10.1038/nprot.2007.135 (2007).
71. Vaziri, C. et al. A p53-dependent checkpoint pathway prevents rereplication. Mol Cell 11, 997–1008 (2003).
72. Liu, E. et al. The ATR-mediated S phase checkpoint prevents rereplication in mammalian cells when licensing control is disrupted. J Cell Biol 179, 643–657 (2007).
73. Chen, L., Nievera, C. J., Lee, A. Y. & Wu, X. Cell cycle-dependent complex formation of BRCA1:ChIP:MRN is important for DNA double-strand break repair. The journal of biological chemistry 283, 7713–7720, https://doi.org/10.1074/jbc.M710245200 (2008).
Acknowledgements
The authors thank Dr. Xiaohua Wu (Department of Molecular and Experimental Medicine, The Scripps Research Institute, CA, USA) for kindly providing the adenovirus constructs and Dr. Maria Jasin for U2OS expressing DR-GFP. This work was supported by grants from the Ministry of Science and Technology (MOST102-2320-B-400-014 and MOST105-2628-B-400-003-MY3), Ministry of Health and Welfare (MOHW106-TDU-B-212-122015), and National Health Research Institutes (105A1-CA-PP-07), Taiwan to A. Y.-L. Lee.

Author Contributions
A.N.C. and A.Y.-L.L. conceived the project. A.N.C. designed the study and performed most of the experiments. C.-C.F. collected tissue blocks of clinical OSCC patients and performed IHC staining. Y.-K.L. and I.-H.L. performed immunoblot analysis. H.-C.W. provided. DNA HR repair tools and suggestions. S.-Y.L. performed the identification of phosphorylation sites in HSP90α at S164 and S263 by mass spectrometry analysis. H.-F.J. performed the phosphoproteomic experiment. C.-H.C., I.-S.C., and S.S.J. performed the Spearman correlation and multivariate Cox proportional hazard analysis. P.-C.L. and C.-L.K. provided discussion and suggestions to the experiment or the manuscript. A.N.C., C.-C.F., and A.Y.-L.L. wrote the manuscript with input from all authors.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-17126-2.

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017